UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 185

Sortiert nach

Systemic Treatment of Soft Tissue Sarcomas in the Geriatric Population

Current treatment options in oncology, 2022-06, Vol.23 (6), p.855-863

Weiss, Mia C.

2022

Volltextzugriff (PDF)

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Clinical cancer research, 2024-02, Vol.30 (4), p.649

2024

Volltextzugriff (PDF)

Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma

Clinical cancer research, 2022-02, Vol.28 (4), p.571-572

2022

Volltextzugriff (PDF)

Tilting the Balance, and Gantry, Towards Preservation of Function

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.280-280

2022

Volltextzugriff (PDF)

The clinical utility of next-generation sequencing for bone and soft tissue sarcoma

Acta oncologica, 2022-01, Vol.61 (1), p.38-44

2022

Volltextzugriff (PDF)

Relapsed Synovial Sarcoma: Treatment Options

Current treatment options in oncology, 2023-03, Vol.24 (3), p.229-239

2023

Volltextzugriff (PDF)

Mice Deficient in Dual Oxidase Maturation Factors Are Severely Hypothyroid

Molecular endocrinology (Baltimore, Md.), 2012-03, Vol.26 (3), p.481-492

2012

Volltextzugriff (PDF)

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

Journal of clinical medicine, 2023-03, Vol.12 (7), p.2561

2023

Volltextzugriff (PDF)

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Genes, 2022-10, Vol.13 (11), p.1932

2022

Volltextzugriff (PDF)

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

Rare tumors, 2021, Vol.13, p.20363613211052498-20363613211052498

2021

Volltextzugriff (PDF)

COL1A1::PDGFB fusion-associated uterine sarcoma and response to Imatinib: A case report

Gynecologic oncology reports, 2023-10, Vol.49, p.101270, Article 101270

2023

Volltextzugriff (PDF)

367 Pharmacokinetic and immunologic data from a phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A395-A395

2021

Volltextzugriff (PDF)

Tazemetostat as a treatment for epithelioid sarcoma

Expert opinion on orphan drugs, 2020-09, Vol.8 (9), p.311-315

2020

Volltextzugriff (PDF)

The Clinical and Economic Implications of Different Treatment Pathways for Patients With Rapidly Recurrent Malignant Pleural Effusion

Chest, 2024-06

2024

Volltextzugriff (PDF)

Bortezomib‐Cyclophosphamide‐Dexamethasone (VCD) versus Bortezomib‐Thalidomide‐Dexamethasone (VTD) ‐based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta‐analysis

British journal of haematology, 2014-09, Vol.166 (5), p.702-710

2014

Volltextzugriff (PDF)

Clinical and economic burden of regularly transfused adult patients with β‐thalassemia in the United States: A retrospective cohort study using payer claims

American journal of hematology, 2019-05, Vol.94 (5), p.E129-E132

2019

Volltextzugriff (PDF)

Clinical and Economic Burden of Transfusion-Dependent β-Thalassemia in Adult Patients in the United States

Blood, 2017-12, Vol.130, p.2095-2095

2017

Volltextzugriff (PDF)

Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University Medical Center’s experience

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e22552-e22552

2019

Volltextzugriff (PDF)

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS11587-TPS11587

2023

Volltextzugriff (PDF)

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11565-11565

2023

Volltextzugriff (PDF)

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS11578-TPS11578

2021

Volltextzugriff (PDF)

Interim phase 1 results for SQ3370 in advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3085-3085

2022

Volltextzugriff (PDF)

Development of an Oncologist-Driven Integrative Intervention for Symptom Management in an Academic Cancer Center

Journal of oncology practice, 2019-01, Vol.15 (1), p.30

2019

Volltextzugriff (PDF)

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA11504-LBA11504

2023

Volltextzugriff (PDF)

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11505-11505

2023

Volltextzugriff (PDF)

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systemic Treatment of Soft Tissue Sarcomas in the Geriatric Population

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma

Tilting the Balance, and Gantry, Towards Preservation of Function

The clinical utility of next-generation sequencing for bone and soft tissue sarcoma

Relapsed Synovial Sarcoma: Treatment Options

Mice Deficient in Dual Oxidase Maturation Factors Are Severely Hypothyroid

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

COL1A1::PDGFB fusion-associated uterine sarcoma and response to Imatinib: A case report

367 Pharmacokinetic and immunologic data from a phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform

Tazemetostat as a treatment for epithelioid sarcoma

The Clinical and Economic Implications of Different Treatment Pathways for Patients With Rapidly Recurrent Malignant Pleural Effusion

Bortezomib‐Cyclophosphamide‐Dexamethasone (VCD) versus Bortezomib‐Thalidomide‐Dexamethasone (VTD) ‐based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta‐analysis

Clinical and economic burden of regularly transfused adult patients with β‐thalassemia in the United States: A retrospective cohort study using payer claims

Clinical and Economic Burden of Transfusion-Dependent β-Thalassemia in Adult Patients in the United States

Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University Medical Center’s experience

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma

Interim phase 1 results for SQ3370 in advanced solid tumors

Development of an Oncologist-Driven Integrative Intervention for Symptom Management in an Academic Cancer Center

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Suchergebnisse filtern